Business
Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy
Data Show mdHACM Mitigates Effects of Inflammatory-Induced Degeneration in Chondrocytes, the Primary Cell Type in Cartilage; May Mitigate Vessel Formation and
About this update from Mimedx Group, Inc
[{"type":"text","content":"Data Show mdHACM Mitigates Effects of Inflammatory-Induced Degeneration in Chondrocytes, the Primary Cell Type in Cartilage; May Mitigate Vessel Formation and Repair MARIETTA, Ga., Nov. 01, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion chorion membrane (mdHACM) for the treatment of debilitating conditions involving degeneration of connective tissue: osteoarthritis (OA) and tendinopathy. The first study, published in Osteoarthritis and Cartilage Open, identified a novel mechanism of action by which PURION® Processed mdHACM regulates degradative processes in human articular chondrocytes, the primary cell type comprising articular cartilage. These results further support mdHACM as an investigational new drug (IND) candidate for the treatment of OA and highlight potential disease modifying activities. The second study, published in the Journal of Biomedical Materials Research, Part B, examined chronicity and poor outcomes following tendon injury attributable to prolonged inflammation and hypervascularity. These complications were modeled in vitro for the purposes of evaluating mdHACM as a treatment for tendinopathy, which led to the identification of specific mechanisms responsible for counteracting these disease processes. “These studies reaffirm our commitment to advancing the science of amniotic tissue,” said Timothy R. Wright, MIMEDX Chief Executive Officer. “Through our continued investment in research and clinical development, we aim to demonstrate the utility of PURION® Processed mdHACM as a platform for regenerative medicine. With each new study, we broaden our understanding of the product’s mechanism of action and further our potential for applying these scientific findings to advance meaningful medicines in areas of unmet clinical need.” About the Osteoarthritis (OA) Study (Osteoarthritis & Cartilage Open Journal) With more than 300 million global cases of hip and knee OA and the current treatment paradigm focusing primarily on symptomatic relief (Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injections) followed by prosthetic joint replacement when needed, developing a regenerati...